Additional signals include restoration of nephrin/podocin and α-Klotho [174], protection of actin cytoskeleton and podocyte density in a nondiabetic proteinuric model [175], reduced podocyte lipotoxicity in Alport syndrome [176], and decreased urinary albumin with a related SGLT2 inhibitor [177]. Here, SLC5A2 is linked to Alport syndrome.